ArQule, Inc. (Nasdaq: ARQL) disclosed this morning that it was informed by its Asian partner Kyowa Hakko Kirin that it has temporarily suspend patient enrollment in its ongoing Phase 3 ATTENTION trial on the recommendation of an independent Safety Review Committee in Japan after the reporting of suspected cases of interstitial lung disease in the study. From the filing: ArQule, Inc. (ArQule) has been informed by Kyowa Hakko Kirin Co., Ltd. (Kyowa), which has exclusive development rights to tivantinib in Japan and certain parts of Asia, of Kyowa’s decision to temporarily suspend patient enrollment in its ongoing Phase 3 ATTENTION (Asian Trial of Tivantinib plus Erlotinib for NSCLC without EGFR Mutation) trial.